Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors

International Journal of Cancer

Volumn 94, Issue 6, 2001, Pages 842-849

  Elzey, Bennett D ^a,b,c   Robert Siemens, D ^a   Ratliff, Timothy L ^a   Lubaroff, David M ^a,d  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Cancer vaccine; Immunotherapy; Prostate cancer; Tumor immunology

Indexed keywords

BETA GALACTOSIDE; CANCER VACCINE; CD8 ANTIGEN; CYTOKINE; INTERLEUKIN 12; INTERLEUKIN 2; PROSTATE SPECIFIC ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANARYPOX VIRUS; CONTROLLED STUDY; GENE TARGETING; HUMAN ADENOVIRUS 5; HUMORAL IMMUNITY; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR CELL DESTRUCTION; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; CANARYPOX VIRUS; CYTOKINES; GENE THERAPY; HUMANS; IMMUNIZATION; INTERLEUKIN-12; INTERLEUKIN-2; MALE; MICE; MICE, INBRED BALB C; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, SYNTHETIC;

EID: 0035892365     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1556     Document Type: Article

References (40)

1. Prostate specific antigen role and function
2. Molecular forms of prostate-specific antigen and the human kallikrein gene family: A new era
3. Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP
4. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end-points
5. Winchester: Patterns of care for carcinoma of the prostate gland: Results of a national survey of 1984 and 1990
6. Cancer statistics, 2000
7. Analysis of fixation effects on immunohistochemical localization of prostatic specific antigen in human prostate
8. Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine
9. Expression of human prostate-specific antigen (PSA) in a mouse tumor cell line reduces tumorigenicity and elicits PSA-specific cytotoxic T lymphocytes
10. A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): Safety and immunogenicity in a non-human primate
11. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen
12. Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro
13. Effect of canarypox (ALVAC)-mediated cytokine expression on murine prostate tumor growth
14. Demonstration of a rational strategy for human prostate cancer gene therapy
15. Cytokine mediated immuno-gene therapy in a rat prostate cancer model
16. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer
17. Interleukin-2 transfected prostate cancer cells generate a local antitumor effect in vivo
18. Autoaggression and tumor rejection: It takes more than self-specific T-cell activation
19. + T cell adoptive immunotherapy
20. Immunotherapy of prostate cancer in the Dunning rat model: Use of cytokine gene modified tumor vaccines
21. Characterization of the gene for prostate-specific antigen, a human glandular kallikrein
22. Expression of Escherichia coil beta-galactosidase and rat HPRT in the CNS of Macaca mulatta following adenoviral mediated gene transfer
23. A new technique for the assay of infectivity of human adenovirus 5 DNA
24. Adenovirus-mediated in vivo gene transfer and expression in normal rat liver
25. Genetic predispositon and mesenchymal-epithelial interactions in ras + myc-induced carcinogenesis in reconstitued mouse prostate
26. A human β-actin expression vector system directs high-level accumulation of antisense transcripts
27. Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) virus expressing the HIV-1 envelope glycoprotein
28. Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL
29. Methodology of using vaccinia virus to express foreign genes in tissue culture
30. Persistence of memory CD8 T cells in MHC class I-deficient mice
31. In vivo priming of two distinct antitumor effector populations: The role of MHC class I expression
32. Viral vector delivery in solid-state vehicles: Gene expression in a murine prostate cancer model
33. Adenoviral vectors for gene transfer
34. Immunotherapy of cancer with genetically modified tumor vaccines
35. In situ cytokine gene transfection using vaccinia virus vectors
36. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines
37. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulation factor using ex vivo gene transfer
38. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer
39. Canarypox virus-mediated interleukin 12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long term antitumoral immunity
40. The presence of prostate-specific antigen-related genes in primates and the expression of recombinant human prostate-specific antigen in a transfected murine cell line